Eric Rowinsky

Biography

Dr. Rowinsky’s professional focus is on the development and registration of anticancer therapeutics and impactful diagnostics. Dr. Rowinsky serves as an Executive Director and President at RGenix, a life sciences company focused on discovering new cancer targets using microRNA. Dr. Rowinsky also has purview for clinical development and regulatory affairs. Additionally, Dr. Rowinsky serves as Chief Scientific Officer of Clearpath Development Co., which rapidly advances development stage therapeutic assets to pre-defined human Proof-of-Concept milestones. From 2012 to 2015, Dr. Rowinsky was the Head of Research and Development, Chief Medical Officer, and Executive Vice President of Stemline Therapeutics. In 2010, Dr. Rowinsky co-founded Primrose Therapeutics and became its Chief Executive Officer until it was acquired by Eli Lilly in 2011. From 2004 to 2010, he served as Chief Medical Officer and Executive Vice President of Clinical Development and Regulatory Affairs of ImClone Systems Incorporated, a life sciences company focused on monoclonal antibodies; his team was responsible for development plans that resulted in the regulatory approval of cetuximab and ramucirumab in several indications, as well as nectumumab

Research Interest

Oncology